Aviva PLC Sage Therapeutics, Inc. Transaction History

Aviva PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $1.95 Million - $2.9 Million	-63,507 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$37.06 - $47.11 $984,276 - $1.25 Million	26,559 Added 71.88%	63,507 $2.7 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $1.49 Million - $2.12 Million	36,948 New	36,948 $1.64 Million
Q2 2021 Aug 10, 2021	SELL	$54.88 - $79.29 $922,368 - $1.33 Million	-16,807 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$70.65 - $96.76 $1.19 Million - $1.63 Million	16,807 New	16,807 $1.26 Million
Q1 2020 May 14, 2020	SELL	$26.15 - $77.24 $326,482 - $964,341	-12,485 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$60.18 - $154.77 $751,347 - $1.93 Million	12,485 New	12,485 $901,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.